Tetrazole derivatives
US-2024382468-A2 · Nov 21, 2024 · US
Methods of purifying anti-interleukin-13 antibodies
US9107945B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9107945-B2 |
| Application number | US-96637710-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 13, 2010 |
| Priority date | Sep 30, 2005 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma.
First claim
Opening claim text (preview).
The invention claimed is: 1. A process for purifying an IL-13 antibody comprising more than one chromatographic separation steps, wherein each of said separation steps comprises elution with a single acetate buffer comprising 50 mM sodium acetate and 85 mM sodium chloride buffered to a pH of 3.5-7.0. 2. The process of claim 1 , wherein the chromatographic separation steps are selected from the group consisting of affinity chromatography and ion exchange chromat…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9107945B2 cover?
- The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic…
- Who is the assignee on this patent?
- Hope Claire Louise, Bannister Karen, Fish Brendan Cormick, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/02. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).